Eversept Partners LP Makes New $3.75 Million Investment in Compass Pathways PLC Sponsored ADR $CMPS

Eversept Partners LP bought a new stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) during the first quarter, according to its most recent filing with the SEC. The firm bought 677,924 shares of the company’s stock, valued at approximately $3,749,000. Eversept Partners LP owned about 0.50% of Compass Pathways at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. RTW Investments LP increased its position in Compass Pathways by 0.6% in the 4th quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock worth $60,426,000 after buying an additional 50,000 shares during the period. Nantahala Capital Management LLC grew its stake in shares of Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after acquiring an additional 1,350,698 shares during the last quarter. Millennium Management LLC grew its stake in shares of Compass Pathways by 39.9% in the third quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock worth $15,562,000 after acquiring an additional 774,090 shares during the last quarter. Toronto Dominion Bank grew its stake in shares of Compass Pathways by 152.9% in the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock worth $17,447,000 after acquiring an additional 1,529,013 shares during the last quarter. Finally, ARK Investment Management LLC increased its position in Compass Pathways by 1.6% during the fourth quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock worth $14,876,000 after acquiring an additional 34,894 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CMPS shares. Wall Street Zen upgraded shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. TD Cowen restated a “buy” rating on shares of Compass Pathways in a research report on Monday, June 1st. Royal Bank Of Canada boosted their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Compass Point set a $25.00 price objective on shares of Compass Pathways in a research report on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.36.

Compass Pathways Price Performance

NASDAQ:CMPS opened at $11.27 on Tuesday. The company has a 50-day moving average of $12.52 and a 200-day moving average of $9.06. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -3.58 and a beta of 2.47. Compass Pathways PLC Sponsored ADR has a 52 week low of $3.92 and a 52 week high of $15.40. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.32 and a current ratio of 3.32.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. As a group, equities research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

Compass Pathways Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.